Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Bronchoscopes Market size was over USD 3.7 billion in 2024 and is estimated to reach USD 11.8 billion by the end of 2037, expanding at a CAGR of 10.2% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of the bronchoscopes is assessed at USD 4 billion.
The rising incidences of pulmonary disorders, such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer (LC), and associated infections, are fueling demand in the bronchoscopes market. According to an NLM article from May 2022, the worldwide COPD prevalence among people aged between 30 and 79 accounted for 10.3%. Another 2023 NLM study concluded that the number of asthma patients in the world was over 300.0 million. On the other hand, the count of new and mortal LC cases across the globe in 2022 was 2.4 million and 1.8 million, respectively, which is projected to reach 4·6 million and 3·5 million by 2050: ScienceDirect. These figures signify the need for availing adequate medical facilities, including bronchoscopy, to conduct early diagnosis and intervention.
The efforts from both public and private organizations to make these procedures more accessible are igniting wide adoption in the bronchoscopes market. The cost of related services highly depends on the payers’ pricing for these instruments, pushing companies to introduce affordable and effective options. In this regard, a study from Aalborg University published in August 2022 recognized the cost-effectiveness of reusable flexible bronchoscopies (USD 266.0), embarking on a USD 23.0 difference from the single-use ones (USD 289.0). However, the cost per procedure may vary with the difference in clinical settings, study methods, and scale of patient-volume. Many comparative cost analyses of single-use and reusable flexible items are presented by indifferent study cohorts (presented below).
Cost Comparison Between Single-Use and Reusable Bronchoscopies in Global Settings (2022)
|
Type of Study |
Cost per Reusable Procedure (in USD) |
Cost per Single-use Procedure (in USD) |
|
Châteauvieux |
95.0 |
280.9 |
|
Videau |
250.0 |
320.3 |
|
Debraine |
345.0 |
277.0 |
|
Wojcik |
334.0 |
291.0 |
|
Ofstead |
509.0 |
303.0 |
|
Robert |
256.0 |
257.0 |
|
Bertucat |
133.0 |
178.0 |
|
Fournier |
294.0 |
313.0 |
|
Valentin |
204.0 |
259.0 |
|
Yassin and Smith |
225.0 |
261.0 |
Source: 2022 NLM Study
Bronchoscopes Sector: Growth Drivers and Challenges
Growth Drivers
- Improvements in technological functions and designs: Innovations in the bronchoscopes market are bringing enhanced visualization, maneuverability, and convenience to the procedures. This is escalating the utility of these tools, attracting more consumers to invest in this field. For instance, in April 2024, Moffitt Cancer Center introduced a new platform for attaining better visual effects and access to lesions during ion robotic bronchoscopy. The revolutionary technology is backed by fiber optics and small-sized catheter to enable early detection in lung cancer. Further, the recent integration of high-definition and 4K resolution imaging levitates patient outcomes and product efficacies.
- Inflating demand for minimally invasive procedures: As the consumer preference shifts towards surgical methods with reduced recovery time and number of incisions, the tendency to implement robotics in the bronchoscopes market rises. In comparison to conventional approaches, these minimally invasive interventions are proven to be less risky, making bronchoscopy a widely used treatment. On this note, in June 2023, NLM published a study on the efficacy of a minimally invasive bronchoscopic approach in treating pulmonary infection. It highlighted 0% mortality in such technique, whereas the traditional surgical method presented 9.7%, 17.6%, and 33.3% rates of mortality for samples with 25000, 50000, and 100000 viable bacteria or fungi.
Challenges
- Volatility in pricing and availability: Installation and implementation in the bronchoscopes market require a significant initial investment. Particularly, the advanced and high-definition models may become expensive for many healthcare settings. Specifically in underserved areas, the adoption of these tools is less, restricting exposure in this sector. In addition, lack of financial support from the government and reimbursement policies may prevent both patients and organizations from investing.
- Limitations in supply of essential resources: Recruiting skilled operators with proper knowledge about the products from the bronchoscopes market is becoming difficult. The proper utilization of these commodities requires specialized training. However, the low-resource regions lack in offering such expertise, limiting wide adoption in this field. Moreover, the insufficient supply of repair tools and essential accessories also impacts the durability and effectiveness of such scopes, diluting the interest of investors.
Bronchoscopes Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.2% |
|
Base Year Market Size (2024) |
USD 3.7 billion |
|
Forecast Year Market Size (2037) |
USD 11.8 billion |
|
Regional Scope |
|
Bronchoscopes Segmentation
Usage (Reusable Bronchoscope, Disposable Bronchoscope)
In terms of usage, the reusable bronchoscope segment is likely to dominate over 68.2% bronchoscopes market share by 2037. The major growth factor in this sub-type is cost-efficiency and contribution to reduce medical waste. The emphasizing economic burden of out-of-pocket healthcare expenses associated with predominant pulmonary ailments is pushing companies to introduce more financially assessable options. In 2024, the total expenditure on COPD in the U.S. was predicted to range between USD 33.0 billion and USD 60.0 billion. The same is projected to be USD 82.0 billion and USD 150.0 billion by 2034: ScienceDirect. Thus, except for infectious cases, this type of minimally invasive device is highly effective and desired in mitigating affordability barriers by offering multiple utilities.
End user (Hospitals, Diagnostic Centers, Others)
Based on end user, the hospital segment is poised to attain the highest share in revenue generation from the bronchoscopes market throughout the forecasted timeframe. These organizations are one of the biggest economic contributors in the healthcare industry, making them the primary consumer base for this sector. In this regard, IBEF reported that the hospital industry in India was estimated to be at USD 98.9 billion in 2023, exhibiting a CAGR of 8.0% and totaling USD 193.5 billion by 2032. This highlights the significance of this segment in fostering a profitable business environment for global leaders, particularly in emerging marketplaces. Furthermore, the increasing public and private funding for the infrastructural development of hospitals is fueling a stable capital influx in this sub-type.
Our in-depth analysis of the global bronchoscopes market includes the following segments:
|
Usage |
|
|
End user |
|
|
Product Type |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBronchoscopes Industry - Regional Synopsis
North America Market Analysis
North America bronchoscopes market is set to capture revenue share of around 43.5% by the end of 2037. The well-established medical system of this region is one of the primary drivers in this field. The expansion of healthcare services, incorporating diagnosis and intervention, is also fueling expansion in this landscape. The close association of bronchoscopes with the endoscopes industry, where North America is poised to dominate with a 40.0% share in global revenue by 2037, is evidence of this region’s proprietorship in this sector. Further, the magnifying patient pool and rising awareness about preventive measures are propelling investments in bronchoscopes.
The U.S. bronchoscopes market is pledged to the heightening incidences of respiratory illnesses and favorable regulatory framework. The count of adults diagnosed with COPD by physicians in this country accounted for 14.2 million in 2021, as per the Centers for Disease Control and Prevention report. On the other hand, the American Lunch Association stated that the prevalence of this condition in people aged over 65 in the U.S. was 9.7% in 2022. Thus, this marketplace is becoming a lucrative trading opportunity for global pioneers. This can be testified by the entry of PENTAX Medical in the U.S. with the launch of the EB‑J10 Series Bronchoscopes with FDA 510(k) clearance in September 2020.
Canada is fueling the bronchoscopes market with continuous government efforts to increase healthcare accessibility for older citizens. Considering the impact of aging on the increment of pulmonary ailment cases, the national authorities are proactively cultivating resources by investing in R&D. For instance, in August 2021, the government of Canada allocated a USD 61.5 billion fund to accelerate the Canadian Longitudinal Study on Aging (CLSA) to avail high-end medical facilities for these habitats. Furthermore, the improvement in reimbursement policies and insurance coverage are encouraging both consumers and clinical settings to invest in and accommodate such advanced technologies.
APAC Market Statistics
Asia Pacific is predicted to register the highest CAGR in the bronchoscopes market over the forecast period. With academic excellence and a strong emphasis on the medical device industry, this region is emerging as a hub of uplifted production and innovation in this field. The prevalence of related respiratory illnesses across APAC is rising due to the rapidly aging population, increased smoking rates, and heightening air pollution levels. Till 2022, around 4.0 billion habitats in this region were exposed to heavy air pollution, affecting their health significantly (Asia Development Bank). This is pushing research-based institutions and MedTech endeavors to accumulate and discover solutions for early diagnosis and intervention.
India is focusing on the domestic cultivation of the resources from the bronchoscopes market. Government initiatives, which are dedicated to escalating the country’s production and innovation in medical devices, are fueling growth in this landscape. According to a statistical report from the Department of Pharmaceuticals in India, the medical device industry in this nation was valued at USD 11.0 billion in 2020. It is expected to reach USD 50.0 billion by 2030 while exhibiting a CAGR of 16.4%. Further, influential factors such as Made in India campaigns and favorable subsidiary policies are contributing to the improvement of healthcare infrastructure, propelling adoption in this sector.
China is also following the path of advancing manufacturing capacity and clinical discoveries in the bronchoscopes market. The nation encompasses a well-balanced trading atmosphere in this merchandise by fostering reliable supply and distribution channels. On this note, the International Trade Administration revealed that there were 36,570 hospitals in China in 2021, attaining 3.8 billion patient visits. It also stated that the medical device industry in this country is expected to reach USD 48.8 billion by 2026, where around 50.0% of this value is predicted to originate from diagnostic imaging and consumables. This signifies the presence of great opportunities for global pioneers.
Companies Dominating the Bronchoscopes Landscape
- Teleflex Incorporated
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ambu A/S
- Karl Storz SE & Co. KG
- Boston Scientific Corporation
- Cogentix Medical, Inc.
- Richard Wolf GmbH
- Cook Medical
- Verathon
The tendency to upgrade the existing pipeline to improve patient outcomes is currently observed among leaders in the bronchoscopes market. They are incorporating advanced technologies and their R&D capabilities in developing next-generation tools and widening the scope of application. For instance, in August 2023, Ambu gained 510(k) FDA clearance for its fifth-generation bronchoscope portfolio, the Ambu aScope 5 Broncho, to be utilized in highly complex procedures. After receiving marketing allowance from the European Union in March 2023, this regulatory milestone intended to expand the company’s reach in larger marketplaces such as the U.S., Australia, and Japan. These events also indicate the ease of globalization in this field, inspiring others to participate. Such key players are:
In the News
- In January 2024, Ambu A/S attained a new transitional pass-through (TPT) payment category and HCPCS C code for use in bronchoscopic procedures in the hospital outpatient department (HOPD) for its aScope 5 Broncho HD. The upgrade was intended to avail Medicare facilities for patients and is to be affected till December 2026.
- In April 2023, Verathon announced the launch of BFlex 2 to expand its portfolio of single-use bronchoscopes. The next-generation pipeline encompasses four sizes of scopes and enhanced features, helping clinicians offer improved services for adult and pediatric patients across hospital departments.
Author Credits: Radhika Pawar
- Report ID: 7417
- Published Date: Mar 28, 2025
- Report Format: PDF, PPT
